Loading organizations...
§ Private Profile · Caesarea, Israel
V-Wave is a technology company.
V-Wave Ltd. develops percutaneous implantable technologies, with its primary offering being the V-Wave Ventura Interatrial Shunt. This investigational device is designed to manage chronic heart failure by providing an interatrial shunt. The technology has garnered significant regulatory recognition, having received Breakthrough Device Designation from the FDA and CE Marking in the EU, underscoring its potential impact in cardiovascular medicine.
The company was established in Israel in 2009 by a team of medical scientists and engineers. Their founding insight centered on addressing the unmet needs of patients suffering from chronic heart failure through innovative, minimally invasive solutions. This dedicated focus on advanced implantable devices for cardiac conditions has guided the company's development since its inception.
V-Wave’s product is intended for patients battling chronic heart failure, aiming to improve their quality of life and clinical outcomes. Now operating as part of Johnson & Johnson MedTech, the company maintains its foundational mission to introduce breakthrough ideas and technologies that transform how patients are treated and how diseases are managed, driving forward advancements in cardiovascular care.
V-Wave has raised $224.0M across 4 funding rounds.
V-Wave has raised $224.0M in total across 4 funding rounds.
V-Wave has raised $224.0M in total across 4 funding rounds.
V-Wave's investors include Deerfield Management, Aperture Venture Partners, BRM Group, Endeavour Vision, GHS Fund, Israel Secondary Fund, Johnson & Johnson Innovation, Pontifax, Pura Vida Investments, Triventures, BioStar Ventures, Edwards Lifesciences.
V-Wave has raised $224.0M across 4 funding rounds. Most recently, it raised $98.0M Series C in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2021 | $98M Series C | Deerfield Management | Aperture Venture Partners, BRM Group, Endeavour Vision, GHS Fund, Israel Secondary Fund, Johnson & Johnson Innovation, Pontifax, Pura Vida Investments, Triventures | Announced |
| Sep 1, 2020 | $28M Series C | — | Deerfield Management | Announced |
| Apr 1, 2018 | $70M Series C | Deerfield Management | Aperture Venture Partners, BioStar Ventures, BRM Group, Edwards Lifesciences, Endeavour Vision, Israel Secondary Fund, Johnson & Johnson Innovation, Pontifax, Pura Vida Investments, Quark Venture, Triventures | Announced |
| Jan 11, 2016 | $28M Series B | — | BioStar Ventures, BRM Group, Edwards Lifesciences, Johnson & Johnson Innovation, Pontifax, Pura Vida Investments, Triventures | Announced |
# V-Wave: Medical Device Company Overview
V-Wave is a medical device company focused on developing innovative cardiovascular implants for patients with heart failure. Founded in Israel in 2009, the company specializes in minimally invasive percutaneous technologies that address a significant treatment gap in heart failure care.[1] V-Wave was acquired by Johnson & Johnson in October 2024 and now operates as part of Johnson & Johnson MedTech.[1][3]
The company's flagship product, the Ventura Interatrial Shunt, is designed to treat heart failure with reduced ejection fraction (HFrEF) by creating a shunt between the left and right atrium to reduce elevated left atrial pressure.[4] This device targets approximately 800,000 patients annually in the U.S. who experience HFrEF, representing a substantial market opportunity.[5] The Ventura has received FDA Breakthrough Device Designation and CE Marking, positioning it as a potentially first-to-market solution in its category.[1][4]
V-Wave was established in 2009 in Israel with a mission to develop percutaneous implantable technologies for chronic heart failure patients.[1] The company was built on a foundation of science, engineering, and medicine, drawing on decades of expertise in these fields.[4]
The company gained significant momentum through regulatory recognition: it received FDA Breakthrough Device Designation for heart failure in August 2019 and a second breakthrough designation for pulmonary arterial hypertension in September 2019, followed by CE Marking in 2020.[5] Johnson & Johnson began investing in V-Wave in 2016, eventually leading to the company's acquisition announcement in August 2024 for an upfront payment of $600 million, with potential milestone payments up to $1.1 billion.[3][5] The acquisition closed on October 9, 2024.[3]
V-Wave operates within the structural interventional cardiology sector, addressing a growing clinical need as heart failure prevalence increases globally. The company's acquisition by Johnson & Johnson reflects broader industry trends: major healthcare conglomerates are consolidating innovative medical device startups to expand their cardiovascular portfolios and reach specialized cardiologist networks.[3]
The timing of V-Wave's acquisition is significant because it demonstrates J&J's strategic commitment to heart failure treatment innovation. The company complements J&J MedTech's existing platforms addressing coronary artery disease, peripheral artery disease, heart recovery, and atrial fibrillation, creating a more comprehensive cardiovascular ecosystem.[3] V-Wave's technology also deepens J&J's relationships with structural interventional cardiologists and heart failure specialists, expanding its influence in a specialized but high-impact medical segment.
V-Wave's integration into Johnson & Johnson MedTech positions the Ventura Interatrial Shunt for accelerated clinical adoption and market penetration. With J&J's manufacturing scale, regulatory expertise, and global distribution network, the device is well-positioned to achieve market leadership in interatrial shunt therapy.[5] The company's focus on an unmet clinical need—treating approximately 800,000 HFrEF patients annually in the U.S. alone—suggests substantial long-term growth potential.
Looking ahead, V-Wave's influence will likely expand as the Ventura moves through final regulatory pathways and enters clinical practice. The device represents a paradigm shift in heart failure management, offering patients a less invasive alternative to traditional surgical interventions. As heart failure prevalence continues to rise globally due to aging populations and chronic disease burden, V-Wave's technology will play an increasingly important role in the cardiovascular treatment landscape.